Global Vaccines - Market and Technology Forecast to 2028

Global Vaccines - Market and Technology Forecast to 2028

COVID-19 included Market forecasts by Region, by Technology, by Type. Current Market Overview, Market Trends and Leading Company Profiles

The Vaccine protects children from severe disease and vaccine-preventable disease complications that can include limb paralysis, hearing loss, epilepsy, brain injury, and death. A child with a vaccine-preventable disease can be denied school attendance or childcare facilities. Consequently, getting vaccinated against these diseases is a good investment and usually includes insurance cover. The Vaccinations for Children program is a federally funded initiative that provides vaccinations for low-income households at no cost to children.

The rapidly increasing rate of COVID-19 infection worldwide in early 2020 prompted international partnerships and policy efforts to urgently mobilize resources to manufacture multiple vaccines on shorter timetables, with around 159 candidate vaccines examined under various levels of clinical trials. There are multiple teams working on a coronavirus vaccine, with a hope that multiple vaccines can be approved at record speed. Billions of doses are needed to be produced, which implies cooperation is crucial between industry, regulators, and the scientific community. The vaccine must be available in all parts of the world to ensure that there is no virus reservoir left.

 
The total market for the vaccine is estimated at around USD 75 Billion in 2020 and the market is expected to grow to around USD 123 Billion by 2028. The CAGR of the market is accounted for at around 6.4%. By patient type, the vaccine market for pediatric patients is expected to account for the largest share due to the increased collaboration by government and non-government organizations for effective vaccine coverage, mandating the use of vaccines for certain infectious diseases.
 
Scope- 
The study period of the report “Global vaccines- Market and Technology Forecast to 2028” is from 2018-2028, and the forecast period of the report is from 2020-2028.
 
The report is aimed at:
  • The Key drivers, restraints and challenges which are expected to shape the Global Vaccines market are covered in detailed in the report.
  • The key technologies which could have an impact on the Vaccine Market have been covered in detail.
  • The top ten countries have been analyzed in detail with respect to their size of economy, overview of Healthcare sector and government expenditure (2015-2018), preparedness on the epidemics such as SARS, H1H1, COVID-19, country wise Vaccination coverage.
  • The Porter’s Five Forces and the PEST of the Global Vaccines market have been covered in the report.
  • The high growth markets have been identified in the Opportunity Analysis Chapter.
  • The market has been forecasted from 2020- 2028 considering all the factor, which is expected to impact the market.
  • The Scenario Analysis Chapter covers the key scenarios and its impacts on the forecast chapter.
 
Segmentation covered in this report
The market is segmented based on End User, Region, Patient Type, and Technology:

By Patient Type
  • Pediatric Patients
  • Adult Patients
 
Region Wise Segmentation:
  • North America
  • Europe
  • APAC
  • Middle East
  • LATAM
  • ROW
 
By Technology
  • Conjugate vaccines
  • Inactivated and subunit vaccines
  • Live attenuated vaccines
  • Recombinant vaccines
  • Toxoid vaccines
 
Country Level Analysis
  • USA
  • France
  • UK
  • Germany
  • Italy
  • Australia
  • Canada
  • India
  • Egypt
  • South Africa
 
Reasons to buy
  • The new players in the Vaccines market and the potential entrants into this market can use this report to understand the key market trends that are expected to shape this market in the next few years.
  • The Market Analysis Chapter cover the Key Drivers, Restraints and Challenges of the Vaccines Report. The PEST and the Porter’s five forces are covered in detailed in this report.
  • The key technologies that could impact the Vaccines Market have been covered in detailed, an example is the growing implementation of the Nanopatch technology, used in vaccine delivery.
  • The report can be used by sales and marketing team to formulate their medium- and long-term strategies and to reconfirm their short-term plans.
  • The forecast chapter would help the sales team to formulate their medium-term sales plan.
  • The report would be help to the sales and the marketing team to understand the key segments across the top ten countries which have been analyzed in the report.
  • The Opportunity Analysis chapter identifies the key hot spots within the Global Vaccine Market.
  • The company profiles include financials, latest news, contracts, and SWOT for around 10 companies.
 
Who is this report for?
  • Healthcare professionals: They serve as experts in subject matter throughout most of the process of approval and regulatory oversight.
  • Manufacturers and private industry: The production and testing of a vaccine are costly and full of the potential for liability, ensuring that funding should come from private organizations, such as pharmaceutical firms.
  • Nongovernmental Organizations: They can act as an important gateway between societies and manufacturers to facilitate communication in areas where a vaccine is required. 
  • Academy: The academic community performs useful research that can help other stakeholders understand what can be learned about numerous aspects of the development of vaccination. They can promote evidence-based immunization policies, comment on a vaccine's socioeconomic consequences to the population at risk or analyse past studies.
  • Government agencies: In the United States, federal agencies such as the FDA act as the check-and-balance on any vaccine that is made available to consumers.
  • R&D Departments: The R&D departments of vaccine manufacturing companies could use this report to understand the market trends and the vaccine market size.
  • Individuals and communities: The public plays an essential role in assessing vaccine efficacy and safety. From engaging in trials to working as end-users for an approved drug, this group gets down to help recognize the real-world implications of an immunization.
  • Decision Makers: The future investment and technology focus decisions could be formulated based on the inputs of this report.
1  Introduction
1.1  Objective
1.2  Market Introduction
1.3  Market Scope
1.4  Methodology
1.5  Scenario based Forecast
1.6  Who will benefit from this report?
1.6.1  Business Leaders & Business Developers
1.6.2  Vaccines Professionals
1.6.3  Policy Makers, Budget Planners and Decision Makers
1.6.4  Civil Government Leaders & Planners
1.6.5  Financial analysts, Investors, Consultants
1.7  Language

2  Executive Summary
2.1  Vaccines Market Trends and Insights
2.2  Top Five Major Findings
2.3  Major Conclusion
2.4  Important Tables and Graphs

3  Current Market Overview of Global Vaccines Market
3.1  Market Overview
3.2  A Brief History of Vaccination
3.3  Defense Mechanism of Vaccine
3.4  Classification of Vaccines
3.4.1  Live Attenuated Vaccines
3.4.2  Inactivated Vaccines
3.5  Composition of Vaccines
3.6  Vaccine Preventable Diseases

4  Current Market Trends of the Global Vaccines Market
4.1  Stages of Vaccine Development, Testing, and Regulation
4.1.1  Exploratory Stage
4.1.2  Pre-Clinical Stage
4.1.3  Clinical Development
4.1.4  Vaccine Post-Licensure Monitoring
4.1.5  Manufacturing
4.2  Stakeholders in Vaccine Development
4.3  Vaccine Implementation Options
4.3.1  Implementation and Immunization in the US
4.3.2  Implementation and Immunization in Europe
4.3.3  Implementation and Immunization in Asia-Pacific Region
4.4  COVID 19 Vaccine
4.4.1  Vaccine Production
4.4.2  Technology Platforms
4.4.3  Vaccine Candidates
4.4.4  Partnerships

5  Market Technologies
5.1  Reverse Vaccinology
5.2  Structural Vaccinology
5.3  Immunoprophylaxis by gene transfer
5.4  Prefilled AD Injection Devices
5.5  Needle-free vaccine delivery
5.6  Nanopatch Technology
5.7  Ready-to-use Inactivated Vaccines
5.8  Mucosal Vaccination
5.9  Synthetic Antigen Vaccines
5.10  DNA Vaccines

6  Market Dynamics
6.1  Drivers
6.1.1  Increased incidence of infectious diseases
6.1.2  Government Support in Vaccine Development
6.1.3  Enhanced Vaccine R&D
6.1.4  COVID 19 | Impact on Vaccine Market
6.2  Restraints
6.2.1  Huge Capital Investments with the Vaccine Development
6.2.2  Longer timeline required for vaccine development
6.3  Challenges
6.3.1  Supply chain challenges in temperature-controlled vaccines
6.3.2  Social and Political Negligence
6.3.3  Vaccine Hesitancy
6.3.4  Lack of Vaccine Development Knowledge & Infrastructure
6.4  PEST
6.4.1  Political
6.4.2  Economic
6.4.3  Social
6.4.4  Technology
6.5  Porter’s Five Forces
6.5.1  Buyer’s Bargaining Power
6.5.2  Suppliers Bargaining Power
6.5.3  Threat of New Entrants
6.5.4  Threat of Substitutes
6.5.5  Rivalry among Competitors

7  Country Analysis
7.1  United States of America (USA)
7.1.1  Introduction
7.1.2  Healthcare Sector
7.1.3  Vaccination coverage in US
7.2  Canada
7.2.1  Introduction
7.2.2  Healthcare Sector
7.2.3  Vaccination Coverage in Canada
7.3  France
7.3.1  Introduction
7.3.2  Healthcare Sector
7.3.3  Vaccination coverage in France
7.4  United Kingdom (UK)
7.4.1  Introduction
7.4.2  Healthcare Sector
7.4.3  Vaccination coverage in United Kingdom
7.5  Italy
7.5.1  Introduction
7.5.2  Healthcare Sector
7.5.3  Vaccination coverage in Italy
7.6  Germany
7.6.1  Introduction
7.6.2  Healthcare Sector
7.6.3  Vaccination coverage in Germany
7.7  Australia
7.7.1  Introduction
7.7.2  Healthcare Sector
7.7.3  Vaccination coverage in Australia
7.8  India
7.8.1  Introduction
7.8.2  Healthcare Sector
7.8.3  Vaccination coverage in India
7.9  Egypt
7.9.1  Introduction
7.9.2  Healthcare Sector
7.9.3  Vaccination coverage in Egypt
7.10  South Africa
7.10.1  Introduction
7.10.2  Healthcare Sector
7.10.3  Vaccination coverage in South Africa

8  Global Vaccines Market Forecast by Region to 2028
8.1  Total Global Market by Region to 2028
8.2  Total Global Vaccines Market by Region (By Disease Indication) to 2028
8.2.1  North America
8.2.2  Europe
8.2.3  APAC
8.2.4  Middle East
8.2.5  LATAM
8.2.6  Rest of the World
8.3  Total Global Market by Region (By Patient Type) to 2028
8.3.1  North America
8.3.2  Europe
8.3.3  APAC
8.3.4  Middle East
8.3.5  LATAM
8.3.6  Rest of the World

9  Global Vaccines Market Forecast by Technology to 2028
9.1  Total Global Market by Technology to 2028
9.2  Total Global Market by Technology (By Type) to 2028
9.2.1  Conjugate Vaccines
9.2.2  Inactivated and subunit Vaccines
9.2.3  Live attenuated Vaccines
9.2.4  Recombinant Vaccines
9.2.5  Toxoid Vaccines
9.3  Total Global Market by Technology (By Mode of Administration) to 2028
9.3.1  Conjugate Vaccines
9.3.2  Inactivated and subunit Vaccines
9.3.3  Live attenuated Vaccines
9.3.4  Recombinant Vaccines
9.3.5  Toxoid Vaccines

10  Global Vaccines Market Forecast by Patient Type to 2028
10.1  Total Global Vaccines Market by Patient Type to 2028
10.2  Total Global Vaccines Market by Patient Type (By Technology) to 2028
10.2.1  Pediatric patients
10.2.2  Adult patients
10.3  Total Global Vaccines Market by Patient Type (By Mode of Administration) to 2028
10.3.1  Pediatric patients
10.3.2  Adult patients

11  Corona Impact on Vaccines Market
11.1  Introduction
11.2  Corona Scenario-1
11.3  Corona Scenario-2
11.4  Corona Scenario- 3

12  Scenario Analysis
12.1  Introduction
12.2  Scenario Analysis 1
12.3  Scenario Analysis 2

13  Opportunity Analysis
13.1  By Region
13.2  By Technology
13.3  By Patient Type

14  Company Profiling
14.1  Pfizer
14.1.1  Company Profile
14.1.2  Products & Services
14.1.3  Segment Revenue
14.1.4  Financial info (revenues, profit last 5 years)
14.1.5  Recent Contract(s) Won
14.1.6  Recent Projects Completed
14.1.7  Strategic Alliances
14.1.8  SWOT Analysis
14.2  Sanofi
14.2.1  Company Profile
14.2.2  Products & Services
14.2.3  Segment Revenue
14.2.4  Financial info (revenues, profit last 5 years)
14.2.5  Recent Contract(s) Won
14.2.6  Recent Projects Completed
14.2.7  Strategic Alliances
14.2.8  SWOT Analysis
14.3  GlaxoSmithKline (GSK)
14.3.1  Company Profile
14.3.2  Products & Services
14.3.3  Segment Revenue
14.3.4  Financial info (revenues, profit last 5 years)
14.3.5  Recent Contract(s) Won
14.3.6  Recent Projects Completed
14.3.7  Strategic Alliances
14.3.8  SWOT Analysis
14.4  Johnson & Johnson
14.4.1  Company Profile
14.4.2  Products & Services
14.4.3  Segment Revenue
14.4.4  Financial info (revenues, profit last 5 years)
14.4.5  Recent Contract(s) Won
14.4.6  Strategic Alliances
14.4.7  SWOT Analysis
14.5  Merck & Co.
14.5.1  Company Profile
14.5.2  Products & Services
14.5.3  Financial info (revenues, profit last 5 years)
14.5.4  Recent Contract(s) Won
14.5.5  Strategic Alliances
14.5.6  SWOT Analysis
14.6  Novavax
14.6.1  Company Profile
14.6.2  Products & Services
14.6.3  Financial info (revenues, profit last 5 years)
14.6.4  Recent Contract(s) Won
14.6.5  Strategic Alliances
14.6.6  SWOT Analysis
14.7  CSL Limited
14.7.1  Company Profile
14.7.2  Products & Services
14.7.3  Financial info (revenues, profit last 5 years)
14.7.4  Recent Contract(s) Won
14.7.5  Strategic Alliances
14.7.6  SWOT Analysis
14.8  AstraZeneca
14.8.1  Company Profile
14.8.2  Products & Services
14.8.3  Financial info (revenues, profit last 5 years)
14.8.4  Recent Contract(s) Won
14.8.5  Strategic Alliances
14.8.6  SWOT Analysis
14.9  Inovio Pharmaceuticals
14.9.1  Company Profile
14.9.2  Products & Services
14.9.3  Financial info (revenues, profit last 5 years)
14.9.4  Recent Contract(s) Won
14.9.5  Strategic Alliances
14.9.6  SWOT Analysis
14.10  Emergent BioSolutions
14.10.1  Company Profile
14.10.2  Products & Services
14.10.3  Financial info (revenues, profit last 5 years)
14.10.4  Recent Contract(s) Won
14.10.5  Strategic Alliances
14.10.6  SWOT Analysis

15  Strategic Conclusions

16  Appendices
16.1  Companies Mentioned
16.2  Abbreviations

17  About Market Info Group
17.1  General
17.2  Contact us
 
List of tables
Table 1: Examples of Vaccines with preservatives, Global Vaccines Market, 2020-2028
Table 2: Examples of Adjuvanted Vaccines, Global Vaccines Market, 2020-2028
Table 3: Herd Immunity Threshold for some diseases, Global Vaccines Market, 2020-2028
Table 4: Key Participants in each COVID 19 Vaccine, Global Vaccines Market, 2020-2028
Table 5: Buyer’s Bargaining Power, Global Personal Protection Equipment Market, 2020-2028
Table 6: Supplier’s Bargaining Power, Global Vaccine Market, 2020-2028
Table 7: Threat of New Entrants, Global Vaccine Market, 2020-2028
Table 8: Threat of Substitutes, Global Vaccine Market, 2020-2028
Table 9: Competitive Rivalry, Global Personal Protection Equipment Market, 2020-2028
Table 10: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
Table 11: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April’2020 data), Global Vaccines Market,2020-2028
Table 12: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
Table 13: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April’2020 data), Global Vaccines Market,2020-2028
Table 14: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
Table 15: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April’2020 data), Global Vaccines Market,2020-2028
Table 16: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
Table 17: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April’2020 data), Global Vaccines Market,2020-2028
Table 18: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
Table 19: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April’2020 data), Global Vaccines Market,2020-2028
Table 20: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-202
Table 21: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April’2020 data), Global Vaccines Market,2020-2028
Table 22: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
Table 23: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April’2020 data), Global Vaccines Market,2020-2028
Table 24: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
Table 25: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April’2020 data), Global Vaccines Market,2020-2028
Table 26: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
Table 27: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April’2020 data), Global Vaccines Market,2020-2028
Table 28: Vaccination Coverage (in Percentage), Global Vaccines Market,2020-2028
Table 29: Total Cases and Deaths due to major epidemics (In Numbers, As of 30 April’2020 data), Global Vaccines Market,2020-2028
Table 30: Vaccines Market Forecast (Region wise in USD Billion), Global, 2018-2028
Table 31: North America Market Forecast (Disease Indication wise in USD Billion), 2018-2028
Table 32: Europe Market Forecast (Disease Indication wise in USD Billion), 2018-2028
Table 33: APAC Market Forecast (Disease Indication wise in USD Billion),  2018-2028
Table 34: Middle East Market Forecast (Disease Indication wise in USD Billion), 2018-2028
Table 35: LATAM Market Forecast (Disease Indication wise in USD Billion), 2018-2028
Table 36: Rest of the World Market Forecast (Disease Indication wise in USD Billion), 2018-2028
Table 37: North America Market Forecast (Patient Type wise in USD Billion), 2018-2028
Table 38: Europe Market Forecast (Patient Type wise in USD Billion), 2018-2028
Table 39: APAC Market Forecast (Patient Type wise in USD Billion), 2018-2028
Table 40: Middle East Market Forecast (Form wise in USD Billion), 2018-2028
Table 41: LATAM Market Forecast (Patient Type wise in USD Billion), 2018-2028
Table 42: Rest of the World Market Forecast (Patient Type wise in USD Billion), 2018-2028
Table 43: Vaccines Market Forecast (Technology wise in USD Billion), Global, 2018-2028
Table 44: Conjugate Vaccines Market Forecast (Type wise in USD Billion), Global, 2018-2028
Table 45: Inactivated and subunit Vaccines Market Forecast (Type wise in USD Billion), Global, 2018-2028
Table 46: Live attenuated Vaccines Market Forecast (Type wise in USD Billion), Global, 2018-2028
Table 47: Recombinant Vaccine Market Forecast (Type wise in USD Billion), Global, 2018-2028
Table 48: Toxoid Vaccines Market Forecast (Type wise in USD Billion), Global, 2018-2028
Table 49: Conjugate Vaccines Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
Table 50: Inactivated and subunit Vaccines Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
Table 51: Live attenuated Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
Table 52: Recombinant Vaccine Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
Table 53: Toxoid Vaccines Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
Table 54: Vaccines Market Forecast (End-Use Industry wise in USD Billion), Global, 2018-2028
Table 55: Pediatic Patients Vaccines Market Forecast (Technology wise in USD Billion), Global, 2018-2028
Table 56: Adult Patients Market Forecast (Technology wise in USD Billion), Global, 2018-2028
Table 57: Pediatic Patients Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
Table 58: Adult Patients Market Forecast (Mode of Administration wise in USD Billion), Global, 2018-2028
Table 59: Vaccines Market Forecast (USD Billion), Corona Impact CS-1, 2020-2028
Table 60: Vaccines Market Forecast (USD Billion), Corona Impact CS-2, 2020-2028
Table 61: Vaccines Market Forecast (USD Billion), Corona Impact CS-3, 2020-2028
Table 62: Vaccines market (In USD Billion), Scenario Analysis, 2020-2028
Table 63: Vaccines market (In USD Billion), Scenario 1 Analysis, 2020-2028
Table 64: Global Vaccines market (In USD Billion), Scenario 1 Factors, 2020-2028
Table 65: Vaccines market (In USD Billion), Scenario 1 Analysis, 2020-2028
Table 66: Vaccines market (In USD Billion), Scenario 2 Analysis, 2020-2028
Table 67: Vaccines market (In USD Billion), Scenario 2 Factors, 2020-2028
Table 68: Vaccines market (In USD Billion), Scenario 2 Industry wise Analysis, 2020-2028
Table 69: Pfizer Financial Information 2015 – 2019 (USD Billions), Global Vaccines market
Table 70: Sanofi Information 2015 – 2019 (USD Billions), Global Vaccines market
Table 71: GlaxoSmithKline Financial Information 2015 – 2019 (USD Billions), Global Vaccines market
Table 72: Johnson & Johnson Financial Information 2015 – 2019 (USD Billions), Global Vaccines market
Table 73: Merck & Co. Financial Information 2015 – 2019 (USD Billions), Global Vaccines market
Table 74: Novavax Financial Information 2015 – 2019 (USD Billions), Global Vaccines market
Table 75: CSL Limited Financial Information 2015 – 2019 (USD Billions), Global Vaccines market
Table 76: AstraZeneca Financial Information 2017 – 2019 (USD Billions), Global Vaccines market
Table 77: Inovio Pharmaceuticals Financial Information 2016 – 2019 (USD Billions), Global Vaccines market
Table 78: Emergent BioSolutions Financial Information 2015 – 2019 (USD Billions), Global Vaccines market

 
List of figures
Figure 1: Comparison of the Immune Response to a disease-causing Organism and to a Vaccine, Global Vaccines Market, 2020-2028
Figure 2: Progress of Polio Elimination 1988 and 2014, Global Vaccines Market, 2020-2028
Figure 3: Antibody destruction by antigen, Global Vaccines Market, 2020-2028
Figure 4: Live Attenuated Vaccine, Global Vaccines Market, 2020-2028
Figure 5: Inactivated Vaccine, Global Vaccines Market, 2020-2028
Figure 6: Global Vaccine Coverage in 2018, Global Vaccines Market, 2020-2028
Figure 7: Phases of Vaccine Development, Global Vaccines Market, 2020-2028
Figure 8: Exploring the drug development process, Global Vaccines Market, 2020-2028
Figure 9: Clinical Trials, Global Vaccines Market, 2020-2028
Figure 10: Professionals involved in Vaccine Development, Global Vaccines Market, 2020-2028
Figure 11: Immunization policy in US, Global Vaccines Market, 2020-2028
Figure 12: Immunization in Europe, Global Vaccines Market, 2020-2028
Figure 13: Immunization in APAC, Global Vaccines Market, 2020-2028
Figure 14: COVID-19 Virus, Global Vaccine Market, 2020-2028
Figure 15: Covid 19 Vaccine, Global Vaccine Market, 2020-2028
Figure 16: COVID 19- Projected timeline for treatment and prevention, Global Vaccine Market, 2020-2028
Figure 17: COVID 19- Possible treatment and prevention, Global Vaccine Market, 2020-2028
Figure 18: Reverse Vaccinology | Bexsero(meningococcal group B vaccine), Global Vaccines Market, 2020-2028
Figure 19: Structural Vaccinology, Global Vaccine Market, 2020-2028
Figure 20: Immunoprophylaxis by gene versus Traditional Passive Immunization, Global Vaccine Market, 2020-2028
Figure 21: Activation and use of prefilled bubble-like auto-disable injection, Global Vaccine Market, 2020-2028
Figure 22: Needle free vaccine injection, Global Vaccine Market, 2020-2028
Figure 23: Cross-section of Nanopatch Technology, Global Vaccine Market, 2020-2028
Figure 24: Heartwater disease in animals, Global Vaccine Market, 2020-2028
Figure 25: Mucosal Vaccination, Global Vaccine Market, 2020-2028
Figure 26: Synthetic Antigen Vaccine, Global Vaccine Market, 2020-2028
Figure 27: DNA Vaccine, Global Vaccine Market, 2020-2028
Figure 28: Key Drivers, Global Vaccine Market, 2020-2028
Figure 29: Global number of Child deaths due to infectious disease, Global Vaccine Market, 2020-2028
Figure 30: Global Alliance Partner for Vaccination and Immunization(GAVI) , Global Vaccine Market, 2020-2028
Figure 31: Vaccine Ecosystem Interdependancies Chart, Global Vaccine Market, 2020-2028
Figure 32: Total confirmed COVID-19 deaths per million people, Global Vaccine Market, 2020-2028
Figure 33: Key Restraints, Global Vaccines Market, 2020-2028
Figure 34: Vaccine development timeline, Global Vaccine Market, 2020-2028
Figure 35: Key Challenges, Global Personal Protection Equipment Market, 2020-2028
Figure 36: Percentage of respondents for major challenges to vaccine delivery systems, Global Vaccines Market, 2020-2028
Figure 37: Challenges and human responses in Vaccine Development, Global Vaccines Market, 2020-2028
Figure 38: Porter’s Five Forces, Global Vaccines Market, 2020-2028
Figure 39:  Epidemic Response Index, Global Vaccines Market,2020-2028
Figure 40:  Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
Figure 41:  Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
Figure 42:  Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
Figure 43:  Epidemic Response Index, Global Vaccines Market,2020-2028
Figure 44:  Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
Figure 45:  Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
Figure 46:  Epidemic Response Index, Global Vaccines Market,2020-2028
Figure 47:  Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
Figure 48:  Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
Figure 49:  Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
Figure 50:  Epidemic Response Index, Global Vaccines Market,2020-2028
Figure 51:  Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
Figure 52:  Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
Figure 53:  Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
Figure 54:  Epidemic Response Index, Global Vaccines Market,2020-2028
Figure 55:  Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
Figure 56:  Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
Figure 57:  Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
Figure 58:  Epidemic Response Index, Global Vaccines Market,2020-2028
Figure 59:  Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
Figure 60:  Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
Figure 61:  Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
Figure 62:  Epidemic Response Index, Global Vaccines Market,2020-2028
Figure 63:  Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
Figure 64:  Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
Figure 65:  Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
Figure 66:  Epidemic Response Index, Global Vaccines Market,2020-2028
Figure 67:  Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
Figure 68:  Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
Figure 69:  Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
Figure 70:  Epidemic Response Index, Global Vaccines Market,2020-2028
Figure 71:  Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
Figure 72:  Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
Figure 73:  Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
Figure 74:  Epidemic Response Index, Global Vaccines Market,2020-2028
Figure 75:  Government Expenditure on Healthcare (In Percentage), Global Vaccines Market,2020-2028
Figure 76:  Incidence of vaccine preventable diseases, Global Vaccines Market,2020-2028
Figure 77:  Total Cases and Deaths due to major epidemics (In Numbers), Global Vaccines Market,2020-2028
Figure 78: Vaccines Market Forecast (Region wise in USD Billion), Global, 2018- 2028
Figure 79: Vaccines Market Forecast (Region wise, In Percent), Global, 2020-2028
Figure 80: North America Market Forecast (Disease Indication wise in USD Billion), 2020
Figure 81: North America, Vaccines Market Forecast (In Percent), By Disease Indication, 2020-2028
Figure 82: Europe Market Forecast (Disease Indication wise in USD Billion), 2020
Figure 83: Europe, Vaccine Market Forecast (In Percent), By Disease Indication, 2020-2028
Figure 84: APAC Market Forecast (Disease Indication wise in USD Billion), 2020
Figure 85: APAC, Vaccines Market Forecast (In Percent), By Disease Indication, 2020-2028
Figure 86: Middle East Market Forecast (Disease Indication wise in USD Billion), 2020
Figure 87: Middle East, Vaccines Market Forecast (In Percent), By Disease Indication, 2020-2028
Figure 88: LATAM Market Forecast (Disease Indication wise in USD Billion), 2020
Figure 89: LATAM, Vaccines Market Forecast (In Percent), By Disease Indication, 2020-2028
Figure 90: Rest of the World Market Forecast (Disease Indication wise in USD Billion), 2020
Figure 91: Rest of the World, Vaccines  Market Forecast (In Percent), By Disease Indication, 2020-2028
Figure 92: North America Market Forecast (Patient Type wise in USD Billion), 2020
Figure 93: North America, Vaccines  Market Forecast (In Percent), By Patient Type, 2020-2028
Figure 94: Europe Market Forecast (Patient Type wise in USD Billion), 2020
Figure 95: Europe, Vaccines Market Forecast (In Percent), By Form, 2020-2028
Figure 96: APAC Market Forecast (Patient Type wise in USD Billion), 2020
Figure 97: APAC, Vaccines Market Forecast (In Percent), By Patient Type, 2020-2028
Figure 98: Middle East Market Forecast (Patient Type wise in USD Billion), 2020
Figure 99: Middle East, Vaccines Market Forecast (In Percent), By Patient Type, 2020-2028
Figure 100: LATAM Market Forecast (Patient Type wise in USD Billion), 2020
Figure 101: LATAM, Vaccines Market Forecast (In Percent), By Patient Type, 2020-2028
Figure 102: Rest of the World Market Forecast (Patient Type wise in USD Billion), 2020
Figure 103: Rest of the World, Vaccines Market Forecast (In Percent), By Patient Type, 2020-2028
Figure 104: Vaccines Market Forecast (Technology wise in USD Billion), Global, 2018-2028
Figure 105: Vaccines Market Forecast (Technology wise In Percent), Global, 2020-2028
Figure 106: Conjugate Vaccines Market Forecast (Type wise in USD Billion), Global, 2020
Figure 107: Conjugate Vaccines, Vaccines Market Forecast (In Percent), By Type, 2020-2028
Figure 108: Inactivated and subunit Vaccines Market Forecast (Type wise in USD Billion), Global, 2020
Figure 109: Inactivated and subunit Vaccines, Vaccines Market Forecast (In Percent), By Type, 2020-2028
Figure 110: Live attenuated Vaccines, Market Forecast (Type wise in USD Billion), Global, 2020
Figure 111: Live attenuated Vaccines, Vaccines Market Forecast (In Percent), By Type, 2020-2028
Figure 112: Recombinant Vaccine Market Forecast (Type wise in USD Billion), Global, 2020
Figure 113: Recombinant Vaccine, Vaccines Market Forecast (In Percent), By Type, 2020-2028
Figure 114: Toxoid Vaccines Market Forecast (Type wise in USD Billion), Global, 2020
Figure 115: Toxoid Vaccines, Vaccines Market Forecast (In Percent), By Type, 2020-2028
Figure 116: Conjugate Vaccines Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
Figure 117: Conjugate Vaccines, Vaccines Market Forecast (In Percent), By Mode of Administration, 2020-2028
Figure 118: Inactivated and subunit Vaccines Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
Figure 119: Inactivated and subunit Vaccines, Vaccines Market Forecast (In Percent), By Mode of Administration, 2020-2028
Figure 120: Live attenuated, Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
Figure 121: Live attenuated, Vaccines Market Forecast (In Percent), By Mode of Administration, 2020-2028
Figure 122: Recombinant Vaccine Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
Figure 123: Recombinant Vaccine, Vaccines Market Forecast (In Percent), By Mode of Administration, 2020-2028
Figure 124: Toxoid Vaccines Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
Figure 125: Toxoid Vaccines, Vaccines Market Forecast (In Percent), By Mode of Administration, 2020-2028
Figure 126: Vaccines Market Forecast (Source wise in USD Billion), Global, 2018-2020
Figure 127: Vaccines Market Forecast (End-Use Industry wise In Percent), Global, 2020-2028
Figure 128: Pediatic Patients Vaccines Market Forecast (Technology wise in USD Billion), Global, 2020
Figure 129: Pediatic Patients, Vaccines Market Forecast (In Percent), By Technology, 2020-2028
Figure 130: Adult Patients Market Forecast (Technology wise in USD Billion), Global, 2020
Figure 131: Adult Patients, Vaccines Market Forecast (In Percent), By Technology, 2020-2028
Figure 132: Pediatic Patients Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
Figure 133: Pediatic Patients Market Forecast (In Percent), By Mode of Administration, 2020-2028
Figure 134: Adult Patients Market Forecast (Mode of Administration wise in USD Billion), Global, 2020
Figure 135: Adult Patients Market Forecast (In Percent), By Mode of Administration, 2020-2028
Figure 136: Global Vaccines Market (USD Billions), Corona Impact, 2020-2028
Figure 137: Global Vaccines Market (USD Billions), Corona Impact, 2020-2028
Figure 138: Global Vaccines Market (USD Billions), Revenue Impact due to Corona on Vaccines Market, 2020-2028
Figure 139: Global Vaccines Market (USD Billions), Corona Impact CS-1, 2020-2028
Figure 140: Global Vaccines Market (USD Billions), Corona Impact CS-2, 2020-2028
Figure 141: Global Vaccines Market (USD Billions), Corona Impact CS-3, 2020-2028
Figure 142: Vaccines market (In USD Billion), Scenario Analysis, 2020-2028
Figure 143: Vaccines market (In USD Billion), Scenario 1 Analysis, 2020-2028
Figure 144: Vaccines market (In USD Billion), Scenario 1 Type wise Analysis, 2020-2028
Figure 145: Vaccines market (In USD Billion), Scenario 2 Analysis, 2020-2028
Figure 146: Vaccines market (In USD Billion), Scenario 2 Industry wise Analysis, 2020-2028
Figure 147: Global Vaccines Market Forecast (In USD Billion), 2020-2028
Figure 148: Global Vaccines Market CAGR (In Percentage), 2020-2028
Figure 149: Global Vaccines Market Forecast (In USD Billion), 2020-2028
Figure 150: Global Vaccines Market CAGR (In Percentage), 2020-2028
Figure 151: Global Vaccines Market Forecast (In USD Billion), 2020-2028
Figure 152: Global Vaccines Market CAGR (In Percentage), 2020-2028
Figure 153: Pfizer Company Revenue of 2019,Global Vaccines Market, 2020-2028
Figure 154: Pfizer Company Revenue 2015 - 2019 (USD Billions)
Figure 155: Pfizer Company Profit 2015 - 2019 (USD Billions)
Figure 156: Sanofi Revenue of 2018,Global Personal Protective Market Market, 2020-2028
Figure 157: Sanofi Revenue 2015 - 2019 (USD Billions)
Figure 158: Sanofi Profit 2015 - 2019 (USD Billions)
Figure 159: GlaxoSmithKline Company Revenue of 2019,Global Vaccines Market, 2020-2028
Figure 160: GlaxoSmithKline Company Revenue 2015 - 2019 (USD Billions)
Figure 161: GlaxoSmithKline Company Profit 2015 - 2019 (USD Billions)
Figure 162: Johnson & Johnson Company Revenue of 2018,Global Vaccines Market, 2020-2028
Figure 163: Johnson & Johnson Company Revenue 2015 - 2019 (USD Billions)
Figure 164: Johnson & Johnson Company Profit 2015 - 2019 (USD Billions)
Figure 165: Merck Company Revenue of 2018,Global Vaccines Market, 2020-2028
Figure 166: Merck & Co. Company Revenue 2015 - 2019 (USD Millions)
Figure 167: Merck & Co. Company Profit 2015 - 2019 (USD Millions)
Figure 168: Novavax Company Revenue 2015 - 2019 (USD Billions)
Figure 169: CSL Limited Company Revenue 2015 - 2019 (USD Billions)
Figure 170: CSL Limited Company Profit 2015 - 2019 (USD Billions)
Figure 171: AstraZenca Company Revenue of 2018,Global Vaccines Market, 2020-2028
Figure 172: AstraZeneca Company Revenue 2017 – 2019 (USD Billions)
Figure 173: AstraZeneca Company Profit 2017 – 2019 (USD Billions)
Figure 174: Inovio Pharmaceuticals Company Revenue 2015 - 2019 (USD Billions)
Figure 175: Inovio Pharmaceuticals Company Profit 2015 - 2019 (USD Billions)
Figure 176: Emergent BioSolutions Company Revenue 2015 - 2019 (USD Billions)
Figure 177: Emergent BioSolutions Company Profit 2015 - 2019 (USD Billions)


 
Pfizer
Sanofi
GlaxoSmithKline (GSK)
Johnson & Johnson
Merck & Co.
Novavax
CSL Limited
AstraZeneca
Inovio Pharmaceuticals
Emergent BioSolutions
 

Single User License: This license allows for use of a report by one person. This person may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any other person or persons. Unless a Departmental License, a Site License or a Global Site License is purchased, a Single User License must be purchased for every person that wishes to use the report within the same enterprise. Customers who infringe these license terms are liable for a Global Site license fee.

5-User License: This license allows for use of a report by five people within the same enterprise. Each of these people may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any other person or persons. Customers who infringe these license terms are liable for a Global Site license fee.

Site License: This license allows for use of a report by an unlimited number of people within the same enterprise location. Each of these people may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any person or persons outside of the enterprise location. Customers who infringe these license terms are liable for a Global Site license fee.

Global Site License: This license allows for use of a report by an unlimited number of people within the same enterprise worldwide. Each of these people may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any other person or persons outside of the enterprise.

Sample Request

Report Code: MIG200776
Published: June 12, 2020
Pages: 274 (US Letter)
1-User PDF €3,995.00
5-User PDF €4,995.00
Site PDF €6,995.00
Enterprise PDF €7,995.00
Request sample Request more info